Biren Amin
Stock Analyst at Piper Sandler
(3.57)
# 858
Out of 5,240 analysts
74
Total ratings
43.75%
Success rate
9.15%
Average return
Main Sectors:
Stocks Rated by Biren Amin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SLDB Solid Biosciences | Maintains: Overweight | $17 → $18 | $7.38 | +143.90% | 3 | May 13, 2026 | |
| LENZ LENZ Therapeutics | Downgrades: Neutral | $39 → $12 | $8.05 | +49.07% | 3 | May 12, 2026 | |
| ACRS Aclaris Therapeutics | Maintains: Overweight | $7 → $11 | $5.09 | +116.11% | 2 | May 5, 2026 | |
| REGN Regeneron Pharmaceuticals | Assumes: Overweight | $875 | $719.88 | +21.55% | 3 | Mar 31, 2026 | |
| CNTX Context Therapeutics | Maintains: Overweight | $4 → $7 | $2.36 | +196.61% | 2 | Mar 24, 2026 | |
| IMTX Immatics | Assumes: Buy | $18 | $10.79 | +66.82% | 2 | Mar 16, 2026 | |
| ALLO Allogene Therapeutics | Maintains: Overweight | $7 → $8 | $2.33 | +243.35% | 4 | Mar 13, 2026 | |
| KYMR Kymera Therapeutics | Maintains: Overweight | $125 → $140 | $85.59 | +63.57% | 1 | Feb 26, 2026 | |
| OKYO OKYO Pharma | Initiates: Overweight | $7 | $1.62 | +332.10% | 1 | Feb 20, 2026 | |
| CATX Perspective Therapeutics | Initiates: Overweight | $16 | $3.82 | +318.85% | 1 | Feb 19, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $7 | $5.03 | +39.17% | 1 | Nov 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $48 | $21.38 | +124.51% | 1 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $15 → $16 | $18.84 | -15.07% | 12 | Oct 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $93 → $98 | $68.61 | +42.84% | 4 | Oct 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $21 → $31 | $9.24 | +235.50% | 2 | Oct 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $76 → $95 | $61.44 | +54.62% | 2 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $38 | $39.58 | -3.99% | 1 | Mar 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $12 | $1.97 | +509.14% | 1 | Feb 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $74 → $71 | $31.70 | +123.97% | 2 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $35 | $12.15 | +188.07% | 1 | Dec 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $23 → $21 | $22.20 | -5.41% | 3 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $40 → $32 | $41.03 | -22.01% | 2 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $7 → $3 | $3.47 | -13.54% | 1 | Jul 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $120 → $70 | $4.28 | +1,535.51% | 2 | May 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $2,550 | $4.40 | +57,854.55% | 1 | Jan 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $1.70 | +1,311.76% | 1 | Oct 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $34 | $6.67 | +409.75% | 1 | Oct 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $52,500 → $25,000 | $3.06 | +816,893.46% | 2 | Sep 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $16 → $10 | $3.79 | +163.85% | 1 | Jun 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $101 | $62.69 | +61.12% | 1 | Nov 9, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $66 → $69 | $161.32 | -57.23% | 1 | Oct 3, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $155 | $453.06 | -65.79% | 5 | Jul 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $136 | $5.55 | +2,350.45% | 4 | Mar 6, 2017 |
Solid Biosciences
May 13, 2026
Maintains: Overweight
Price Target: $17 → $18
Current: $7.38
Upside: +143.90%
LENZ Therapeutics
May 12, 2026
Downgrades: Neutral
Price Target: $39 → $12
Current: $8.05
Upside: +49.07%
Aclaris Therapeutics
May 5, 2026
Maintains: Overweight
Price Target: $7 → $11
Current: $5.09
Upside: +116.11%
Regeneron Pharmaceuticals
Mar 31, 2026
Assumes: Overweight
Price Target: $875
Current: $719.88
Upside: +21.55%
Context Therapeutics
Mar 24, 2026
Maintains: Overweight
Price Target: $4 → $7
Current: $2.36
Upside: +196.61%
Immatics
Mar 16, 2026
Assumes: Buy
Price Target: $18
Current: $10.79
Upside: +66.82%
Allogene Therapeutics
Mar 13, 2026
Maintains: Overweight
Price Target: $7 → $8
Current: $2.33
Upside: +243.35%
Kymera Therapeutics
Feb 26, 2026
Maintains: Overweight
Price Target: $125 → $140
Current: $85.59
Upside: +63.57%
OKYO Pharma
Feb 20, 2026
Initiates: Overweight
Price Target: $7
Current: $1.62
Upside: +332.10%
Perspective Therapeutics
Feb 19, 2026
Initiates: Overweight
Price Target: $16
Current: $3.82
Upside: +318.85%
Nov 25, 2025
Initiates: Overweight
Price Target: $7
Current: $5.03
Upside: +39.17%
Nov 5, 2025
Initiates: Overweight
Price Target: $48
Current: $21.38
Upside: +124.51%
Oct 30, 2025
Maintains: Neutral
Price Target: $15 → $16
Current: $18.84
Upside: -15.07%
Oct 30, 2025
Maintains: Overweight
Price Target: $93 → $98
Current: $68.61
Upside: +42.84%
Oct 3, 2025
Maintains: Overweight
Price Target: $21 → $31
Current: $9.24
Upside: +235.50%
Sep 25, 2025
Maintains: Overweight
Price Target: $76 → $95
Current: $61.44
Upside: +54.62%
Mar 31, 2025
Initiates: Overweight
Price Target: $38
Current: $39.58
Upside: -3.99%
Feb 19, 2025
Initiates: Overweight
Price Target: $12
Current: $1.97
Upside: +509.14%
Feb 6, 2025
Maintains: Overweight
Price Target: $74 → $71
Current: $31.70
Upside: +123.97%
Dec 2, 2024
Initiates: Overweight
Price Target: $35
Current: $12.15
Upside: +188.07%
Nov 14, 2024
Maintains: Overweight
Price Target: $23 → $21
Current: $22.20
Upside: -5.41%
Nov 6, 2024
Maintains: Neutral
Price Target: $40 → $32
Current: $41.03
Upside: -22.01%
Jul 19, 2024
Downgrades: Hold
Price Target: $7 → $3
Current: $3.47
Upside: -13.54%
May 19, 2023
Maintains: Buy
Price Target: $120 → $70
Current: $4.28
Upside: +1,535.51%
Jan 11, 2021
Initiates: Buy
Price Target: $2,550
Current: $4.40
Upside: +57,854.55%
Oct 30, 2020
Initiates: Buy
Price Target: $24
Current: $1.70
Upside: +1,311.76%
Oct 19, 2020
Initiates: Buy
Price Target: $34
Current: $6.67
Upside: +409.75%
Sep 14, 2020
Downgrades: Hold
Price Target: $52,500 → $25,000
Current: $3.06
Upside: +816,893.46%
Jun 1, 2020
Downgrades: Hold
Price Target: $16 → $10
Current: $3.79
Upside: +163.85%
Nov 9, 2017
Initiates: Buy
Price Target: $101
Current: $62.69
Upside: +61.12%
Oct 3, 2017
Maintains: Buy
Price Target: $66 → $69
Current: $161.32
Upside: -57.23%
Jul 11, 2017
Initiates: Buy
Price Target: $155
Current: $453.06
Upside: -65.79%
Mar 6, 2017
Initiates: Buy
Price Target: $136
Current: $5.55
Upside: +2,350.45%